Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01903291 · ClinicalTrials.gov registry record
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A clinical trial, sponsored by Biogen.
- Completed
- Registry status
- 333
- Enrollment target
NCT01903291 is a clinical trial that has completed, run by Biogen. The registered enrollment target is 333 participants.
The verdict
NCT01903291 has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- 333 participants
- Enrollment target
Study Summary
The primary objective of the study is to estimate the annualized relapse rate (ARR) over a 12-month period in patients with relapsing forms of multiple sclerosis (MS) who are treated with dimethyl fumarate (DMF) after suboptimal response to glatiramer acetate (GA). The secondary objectives of this study in this study population are to assess the impact of DMF over a 12-month period on patient-reported outcomes (PROs) and health economic-related outcomes and to evaluate additional clinical outcomes at Month 12.
Interventions
- DRUG dimethyl fumarate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 333 participants |
| Start Date | 2013-08 |
| Est. Completion | 2016-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01903291
The ClinicalTrials.gov registry entry for NCT01903291 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 333 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which dimethyl fumarate is the first listed.
NCT01903291 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01903291 about?
NCT01903291 is a clinical study titled "Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS". The primary objective of the study is to estimate the annualized relapse rate (ARR) over a 12-month period in patients with relapsing forms of multiple sclerosis (MS) who are treated with dimethyl fumarate (DMF) after suboptimal response to glatiramer acetate (GA). The secondary objectives of this s...
What is the current status of trial NCT01903291?
This trial is currently completed. The enrollment target is 333 participants. The study started on 2013-08. Estimated completion is 2016-02.
What interventions are being tested in trial NCT01903291?
The interventions under investigation include: dimethyl fumarate (DRUG).
Who is sponsoring clinical trial NCT01903291?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.